Gyre Therapeutics, Inc.
GYRE
$8.11
$0.354.51%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 21.37% | -20.86% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 21.37% | -20.86% | |||
| Cost of Revenue | 28.75% | -24.04% | |||
| Gross Profit | 21.05% | -20.72% | |||
| SG&A Expenses | 26.76% | -29.23% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 24.33% | -27.29% | |||
| Operating Income | -4.44% | 242.84% | |||
| Income Before Tax | -51.72% | 500.39% | |||
| Income Tax Expenses | -26.53% | 343.84% | |||
| Earnings from Continuing Operations | -57.79% | 556.24% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -9.46% | -55.09% | |||
| Net Income | -83.62% | 2,825.25% | |||
| EBIT | -4.44% | 242.84% | |||
| EBITDA | 0.18% | 147.62% | |||
| EPS Basic | -83.97% | 2,700.00% | |||
| Normalized Basic EPS | -86.05% | 841.38% | |||
| EPS Diluted | -48.84% | 226.47% | |||
| Normalized Diluted EPS | -85.71% | 727.59% | |||
| Average Basic Shares Outstanding | 3.12% | 0.54% | |||
| Average Diluted Shares Outstanding | 0.72% | 18.64% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||